Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Madrigal Pharmaceuticals (MDGL) Shares Outstanding (2019 - 2025)

Madrigal Pharmaceuticals (MDGL) has disclosed Shares Outstanding for 13 consecutive years, with $22.8 million as the latest value for Q4 2025.

  • Quarterly Shares Outstanding rose 3.81% to $22.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $22.8 million through Dec 2025, up 3.81% year-over-year, with the annual reading at $22.8 million for FY2025, 3.81% up from the prior year.
  • Shares Outstanding for Q4 2025 was $22.8 million at Madrigal Pharmaceuticals, up from $22.7 million in the prior quarter.
  • The five-year high for Shares Outstanding was $22.8 million in Q4 2025, with the low at $2.0 million in Q1 2021.
  • Average Shares Outstanding over 5 years is $10.1 million, with a median of $2.4 million recorded in 2023.
  • The sharpest move saw Shares Outstanding plummeted 87.23% in 2021, then surged 858.07% in 2025.
  • Over 5 years, Shares Outstanding stood at $17.1 million in 2021, then increased by 5.84% to $18.1 million in 2022, then grew by 9.79% to $19.9 million in 2023, then increased by 10.71% to $22.0 million in 2024, then rose by 3.81% to $22.8 million in 2025.
  • According to Business Quant data, Shares Outstanding over the past three periods came in at $22.8 million, $22.7 million, and $22.2 million for Q4 2025, Q3 2025, and Q2 2025 respectively.